| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
DSPE-PEG-NHS does not target a specific biological receptor but serves as a functionalized lipid for nanoparticle formulation. The DSPE lipid moiety anchors into lipid bilayers of liposomes or lipid nanoparticles, while the PEG chain provides steric stabilization and enhances solubility in aqueous environments. The NHS ester group reacts with primary amines (e.g., lysine residues on proteins or antibodies) to form stable amide bonds, enabling surface functionalization of nanoparticles with targeting ligands.
|
|---|---|
| ln Vitro |
In vitro, DSPE-PEG-NHS is used to prepare liposomes or lipid nanoparticles for drug delivery applications. The PEGylation enhances nanoparticle stability and circulation time by reducing opsonization and immune recognition. The NHS ester allows for post-insertion or pre-conjugation of targeting moieties such as antibodies, peptides, or small molecules to the nanoparticle surface. The compound is also used in the development of mRNA vaccine delivery systems.
|
| ln Vivo |
In vivo, DSPE-PEG-NHS is used in the formulation of liposomes and lipid nanoparticles for the delivery of therapeutic agents, including DNA or mRNA vaccines, chemotherapeutics, and targeted drug delivery systems. The PEGylation improves pharmacokinetic properties by extending circulation half-life and reducing non-specific uptake by the reticuloendothelial system. NHS-mediated conjugation enables active targeting of nanoparticles to specific tissues or cells.
|
| Enzyme Assay |
Non-cellular assays for DSPE-PEG-NHS involve characterizing its conjugation efficiency to primary amine-containing molecules. The NHS ester reaction can be monitored by HPLC, mass spectrometry, or UV-Vis spectroscopy to confirm successful conjugation. Liposome formulation studies assess the incorporation of the DSPE-PEG-NHS lipid into lipid bilayers and the resulting particle size, zeta potential, and stability. Binding interactions are not directly measured as this is a formulation component rather than a targeting agent.
|
| Cell Assay |
In vitro cellular experiments with DSPE-PEG-NHS are conducted using liposomes or lipid nanoparticles formulated with this lipid. Cells are treated with the nanoparticles, and cellular uptake, intracellular trafficking, and cytotoxicity are assessed. The PEGylation reduces non-specific cellular uptake, while NHS-mediated conjugation of targeting ligands can enhance specific cell targeting. The compound itself is not directly tested on cells but is a component of the delivery system.
|
| Animal Protocol |
In vivo animal studies using DSPE-PEG-NHS are performed with liposomes or lipid nanoparticles formulated with this lipid. Animal models of disease (e.g., cancer, infectious diseases) are treated with the nanoparticles encapsulating therapeutic agents. Endpoints include biodistribution, pharmacokinetics, therapeutic efficacy, and toxicity. The PEGylation and targeting functionality imparted by DSPE-PEG-NHS contribute to the overall performance of the nanoparticle system.
|
| ADME/Pharmacokinetics |
DSPE-PEG-NHS, MW 2000 has an average molecular weight of 2000 Da. Purity is typically ≥95%. The compound is stored as a powder at -20°C for up to 3 years or at 4°C for up to 2 years, protected from light and under argon. In solvent, it is stable at -80°C for 6 months or at -20°C for 1 month. It is soluble in DMSO (~100 mg/mL with sonication) and other organic solvents. The compound is hygroscopic and should be protected from moisture.
|
| Toxicity/Toxicokinetics |
Toxicity data for DSPE-PEG-NHS are generated as part of the safety evaluation of nanoparticle formulations containing this lipid. The compound itself is generally considered biocompatible and is widely used in pharmaceutical formulations. Standard toxicology studies assess the safety of the final nanoparticle formulation. Researchers should consult the safety data sheet and handle the compound with appropriate laboratory safety precautions.
|
| Additional Infomation |
DSPE-PEG-NHS is also known as DSPE NHS PEG. The IUPAC name is [(2R)-3-[2-[2-[[4-(2,5-dioxopyrrolidin-1-yl)oxy-4-oxobutanoyl]amino]ethoxycarbonylamino]ethoxy-hydroxyphosphoryl]oxy-2-octadecanoyloxypropyl] octadecanoate. The compound is widely used in nanomedicine and targeted drug delivery research. All products are for research use only.
|
| Molecular Weight |
2000(Average)
|
|---|---|
| Appearance |
Typically exists as solid at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~100 mg/mL (with sonication (<60°C))
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one),clear solution.
For example, if 1 mL of working solution is to be prepared,you can add 100 μL of 25.0 mg/mL clear DMSO stock solution and add it to 400 μL PEG300 and mix well. Then add 50 μL Tween-80 to the above system and mix well. Then continue to add 450 μL of physiological saline to make up to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one),clear solution. For example, if 1 mL of working solution is to be prepared,you can add 100 μL of 25.0 mg/mL clear DMSO stock solution and add it to 900 μL of 20% SBE-β-CD saline solution and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one),clear solution. |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
